Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM

IntroductionGlioblastoma (GBM) remains a deadly cancer with non-curative upfront treatment of radiation, resection, and chemotherapy. Not only has the standard of care for GBM patients not improved significantly over the past decade, life expectancy is less than 18 months, with no standard second-li...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Danielle R. Cook, Alina C. Boesteanu, Yibo Yin, Reiss Reid, Laura Roccograndi, Nadia Dahmane, Maria Martinez-Lage, Donald M. O’Rourke, Carl H. June, Laura A. Johnson
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Frontiers Media S.A. 2025-07-01
سلاسل:	Frontiers in Immunology
الموضوعات:	chimeric antigen receptor (CAR) tumor microenvironment (TME) glioblastoma (GBM) checkpoint inhibition (CPI) fourth generation CAR ARMed CAR
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1579925/full
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!